Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (30): 5569-5572.doi: 10.3969/j.issn.1673-8225.2011.30.015

Previous Articles     Next Articles

Meta analysis of 18F-deoxyglucose-positron emission tomography value in evaluation of response to therapy for primary bone and soft tissue sarcomas

Ji Tao1, Zhu Sai-nan2, Guo Wei1, Tang Xiao-dong1, Tang Shun1   

  1. 1Musculoskeletal Tumor Center, People’s Hospital, Peking University, Beijing  100044, China
    2Department of Statistics, Peking University First Hospital, Beijing  100034, China
  • Received:2011-02-26 Revised:2011-05-14 Online:2011-07-23 Published:2011-07-23
  • Contact: Guo Wei, Professor, Doctoral supervisor, Musculoskeletal Tumor Center, People’s Hospital, Peking University, Beijing 100044, China bonetumor@163.com
  • About author:Ji Tao☆, Doctor, Attending physician, Musculoskeletal Tumor Center, People’s Hospital, Peking University, Beijing 100044, China sarcomasurgeon_cn@yahoo.com.cn

PDF

262

Abstract:

BACKGROUND: 18 F-deoxyglucose-positron emission tomography (18FDG-PET) can be used for bone and soft tissue malignant tumor identification, lesion location, degree of malignancy evaluation, biopsy site identification, effect and prognostic assessment.
OBJECTIVE: To assess the value of 18FDG-PET in the evaluation of preoperative therapy response of bone and soft tissue sarcomas by systematic review and meta-analysis.
METHODS: Databases of PubMed, Embase, Cochrane, CNKI, WanFang and VIP databases were searched for articles about PET application in diagnosis and treatment of bone and soft tissue malignant tumor.
RESULTS AND CONCLUSION: Nine non-randomized controlled clinical studies which met the inclusion criteria were included for Meta analysis. Qualitative analysis found recommendation grade B in three studies and C in seven studies. No bias was found in the nine studies. Pooled sensitivity and specificity of cut point 0.5 (SUV2/SUV1) for the prediction of tumor necrosis ≥ 90% were 0.82 (95% confidence interval, 0.72-0.89) and 0.61 (95% confidence interval, 0.49-0.71) respectively. The summary receiver operating characteristic curve (SROC) was 6.17 with 95% confidence interval of 2.84-13.39. Our results indicate that the SUVmax ratio before and after preoperative treatment can predict therapy response with compared high sensitivity, however lack of specificity. Evaluation of preoperative therapy should be determined with combination of 18FDG-PET and others.

CLC Number: